Article
Immunology
Myron J. Levin, Andrew Ustianowski, Steven Thomas, Alison Templeton, Yuan Yuan, Seth Seegobin, Catherine F. Houlihan, Ibrahim Menendez-Perez, Simon Pollett, Rosalinda H. Arends, Rohini Beavon, Kanika Dey, Pedro Garbes, Elizabeth J. Kelly, Gavin C. K. W. Koh, Stefan Ivanov, Karen A. Near, Audrey Sharbaugh, Katie Streicher, Menelas N. Pangalos, Mark T. Esser
Summary: This phase 3 trial evaluated the efficacy of AZD7442 for post-exposure prophylaxis against symptomatic COVID-19. The study did not meet the primary efficacy end point, but analysis of participants who were SARS-CoV-2 RT-PCR-negative or missing an RT-PCR result at baseline supported a role for AZD7442 in preventing symptomatic COVID-19.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Virology
Eloy E. Ordaya, Paschalis Vergidis, Raymund R. Razonable, Joseph D. Yao, Elena Beam
Summary: This study found that most SARS-CoV-2 Omicron subvariants in COVID-19 patients who received Tixagevimab-cilgavimab showed reduced susceptibility to the antibody. Some patients also showed high resistance to Bebtelovimab. The results highlight the importance of genomic surveillance and identification of new resistant variants.
JOURNAL OF CLINICAL VIROLOGY
(2023)
Article
Microbiology
Yinong Young-Xu, Lauren Epstein, Vincent C. Marconi, Victoria Davey, Caroline Korves, Gabrielle Zwain, Jeremy Smith, Fran Cunningham, Robert A. Bonomo, Adit A. Ginde
Summary: In immunocompromised patients, the use of tixagevimab/cilgavimab is associated with lower risks of SARS-CoV-2 infection, COVID-19 hospitalization, and all-cause mortality.
Article
Virology
David Totschnig, Max Augustin, Iulia Niculescu, Hermann Laferl, Sonja Jansen-Skoupy, Clara Lehmann, Christoph Wenisch, Alexander Zoufaly
Summary: This paper provides real-world data on the use of tixagevimab/cilgavimab and sotrovimab as SARS-CoV-2 PrEP in immunocompromised patients. The study shows that sotrovimab maintains higher antibody levels and has a lower incidence of breakthrough infections compared to tixagevimab/cilgavimab.
Article
Oncology
Francesco Angotzi, Marco Petrella, Tamara Berno, Gianni Binotto, Giorgia Bonetto, Antonio Branca, Marco Carraro, Chiara Adele Cavaretta, Alessandro Cellini, Fabio D'Amore, Laura Forlani, Ilaria Gianesello, Carmela Gurrieri, Silvia Imbergamo, Federica Lessi, Antonio Maroccia, Federica Mazzetto, Laura Pavan, Sara Pezone, Francesco Piazza, Stefano Pravato, Valeria Ruocco, Greta Scapinello, Fabrizio Vianello, Renato Zambello, Ivan Zatta, Simone Zoletto, Andrea Padoan, Livio Trentin, Andrea Visentin
Summary: The combination of Tixagevimab/Cilgavimab has been approved to decrease symptomatic SARS-CoV-2 infection in high-risk patients. However, its effectiveness in patients with hematological malignancies remains uncertain. This study prospectively evaluated the rate of infection in seronegative patients receiving Tixagevimab/Cilgavimab compared to seropositive patients observed or given a fourth vaccine dose. The findings showed no significant difference in the incidence of infection between the two groups.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Andrea Lombardi, Giulia Viero, Simone Villa, Simona Biscarini, Emanuele Palomba, Cecilia Azzara, Nathalie Iannotti, Bianca Mariani, Camilla Genovese, Mara Tomasello, Anna Tonizzo, Marco Fava, Antonia Grazia Valzano, Letizia Corinna Morlacchi, Maria Francesca Donato, Giuseppe Castellano, Ramona Cassin, Maria Carrabba, Antonio Muscatello, Andrea Gori, Alessandra Bandera
Summary: Early treatment with TIX/CIL showed favorable outcomes in immunocompromised patients, with no significant difference compared to other mAbs.
Article
Infectious Diseases
Jianhua You, Jiaxin Tian, Haidi Wu, Wenyan Kang, Jianru Wen, Hongwei Xu, Wenbo Shi, Zhi Wang, Hanyu Wei, Yanjun Du, Xiang Li, Guangyuan Mu, Min Zhou, Zhidong Gu, Jieming Qu
Summary: During the COVID-19 pandemic in China, tixagevimab and cilgavimab may have played a role in protecting high-risk populations against infection with the Omicron variant, hospitalization, and severe disease.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2023)
Review
Hematology
Rhea Suribhatla, Thomas Starkey, Maria C. C. Ionescu, Antonio Pagliuca, Alex Richter, Lennard Y. W. Lee
Summary: Immunocompromised patients, especially those with haematological malignancies, have a higher susceptibility to SARS-CoV-2 infection and severe outcomes. This systematic review and meta-analysis demonstrate that tixagevimab/cilgavimab has a significant clinical effectiveness in reducing the risk of COVID-19 infection, hospitalization, intensive care admission, and COVID-19-specific mortality in immunocompromised individuals.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Infectious Diseases
Andrew Ustianowski
Summary: This article emphasizes the importance of the tixagevimab/cilgavimab combination in protecting vulnerable individuals who cannot receive full vaccination or have a poor response to vaccines. The article discusses the ability of this treatment to neutralize emerging variants, appropriate dosage in vulnerable populations, and the impact of prior vaccination on treatment effectiveness.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2022)
Article
Rheumatology
Ioanna Minopoulou, Koray Tascilar, Giulia Corte, Melek Yalcin Mutlu, Katja Schmidt, Daniela Bohr, Fabian Hartmann, Karin Manger, Bernhard Manger, Klaus Korn, Arnd Kleyer, David Simon, Thomas Harrer, Georg Schett, Filippo Fagni
Summary: Passive immunization with the anti-SARS-CoV-2 monoclonal antibodies tixagevimab/cilgavimab is safe and effective in inducing antibody response and potentially preventing COVID-19 in high-risk vaccine-refractory IMID patients. These findings provide a proof of concept for the use of monoclonal antibodies as a preventative strategy against SARS-CoV-2 in vulnerable populations.
Article
Infectious Diseases
F. D. Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simon-Campos, Kenneth Kim, Douglas Arbetter, Kelly W. Padilla, Venkatesh Pilla Reddy, Seth Seegobin, Katie Streicher, Alison Templeton, Rolando M. Viani, Eva Johnsson, Gavin C. K. W. Koh, Mark T. Esser
Summary: This study evaluated the effects of AZD7442 on adult outpatients with COVID-19. It found that AZD7442 reduced the risk of death and hospitalization, and improved symptom severity.
INFECTIOUS DISEASES AND THERAPY
(2023)
Review
Virology
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, Stylianos Daios, Eleni Karlafti, Eleftheria Ztriva, Georgios Polychronopoulos, Charalambos Gogos, Christos Savopoulos
Summary: Effective treatments and vaccines against COVID-19 have had a positive impact on controlling the pandemic, but immunocompromised patients are still at high risk of adverse outcomes. Monoclonal antibodies, such as Tixagevimab/Cilgavimab (AZD7442), have shown promise in reducing the incidence of symptomatic COVID-19 or death in high-risk individuals. Real-world data confirm the efficacy of this antibody combination in lowering the incidence, hospitalization, and mortality associated with COVID-19 in various patient populations. However, vigilance is needed due to the possibility of spike-protein mutations that resist monoclonal antibodies.
Article
Oncology
Andrea Duminuco, Antonella Nardo, Alessandra Orofino, Giuliana Giunta, Concetta Conticello, Vittorio Del Fabro, Annalisa Chiarenza, Marina S. Parisi, Amalia Figuera, Salvatore Leotta, Giuseppe Milone, Alessandra Cupri, Daniela Cambria, Francesco Di Raimondo, Alessandra Romano, Giuseppe A. Palumbo
Summary: Prophylaxis with tixagevimab-cilgavimab in patients with different hematological diseases can mitigate the severity and shorten the duration of SARS-CoV-2 infection. Age, ongoing treatment, baseline diseases, and prior virus exposure are identified as risk factors for subsequent infection.
Article
Rheumatology
Marion Thomas, Maeva Masson, Samuel Bitoun, Sabrina Hamroun, Raphaele Seror, Henry Dupuy, Estibaliz Lazaro, Christophe Richez, Yannick Allanore, Jerome Avouac
Summary: In individuals at risk of severe COVID-19 who are unresponsive to vaccination and have autoimmune or inflammatory diseases, pre-exposure prophylaxis with tixagevimab/cilgavimab is associated with a lower incidence of COVID-19 and no severe infections.
Article
Microbiology
Tiffany L. Roe, Tyler Brady, Nicolette Schuko, Amy Nguyen, Jagadish Beloor, Johnathan D. Guest, Anastasia A. Aksyuk, Kevin M. Tuffy, Tianhui Zhang, Katie Streicher, Elizabeth J. Kelly, Gustavo H. Kijak
Summary: The neutralization activity of AZD7442 against Omicron subvariants was studied, and it was found that AZD7442 maintained neutralization activity against major Omicron subvariants up to and including BA.5, which is important for the prophylaxis and treatment of COVID-19.
MICROBIOLOGY SPECTRUM
(2023)
Article
Infectious Diseases
Emma Oliosi, Geoffrey Rossi, Yann Nguyen, Vasco Honsel, Frederic Bert, Olivier Roux, Bruno Fantin, Agnes Lefort
Summary: This study analyzed the impact of Enterococcus spp. on pyogenic liver abscesses (PLA) outcome. Enterococci were recovered from 19% of the PLA cases, with Enterococcus faecalis and Enterococcus faecium being the most frequent species. Enterococcal PLA were more often of biliary origin or post-surgical. The presence of Enterococcus spp. was independently associated with higher mortality and primary treatment failure in PLA cases.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Dermatology
Anastasia Dupre, Nathalie Morel, Cecile Yelnik, Philippe Moguelet, Veronique Le Guern, Romain Stammler, Yann Nguyen, Romain Paule, Virginie Dufrost, Felix Ackermann, Ygal Benhamou, Bertrand Godeau, Marc Lambert, Pierre Duffau, Arsene Mekinian, David Saadoun, Luc Mouthon, Eric Hachulla, Helene Maillard, Herve Levesque, Sandrine Morell-Dubois, Gaelle Leroux, Jean-Charles Piette, Francois Chasset, Nathalie Costedoat-Chalumeau
Summary: This cohort study investigated the clinical and pathological features of cutaneous involvement during catastrophic antiphospholipid syndrome (CAPS) in 65 patients. The study found that common skin manifestations included livedo racemosa, necrotic lesions, splinter hemorrhages, vascular purpura, and distal inflammatory edema. Skin biopsies confirmed microthrombosis in more than 90% of cases.
Article
Rheumatology
E. Oliosi, A. Flahault, C. Charre, D. Veyer, A. Combier, E. Lafont, A. Karras, L. Mouthon, J. Avouac, B. Terrier, J. Hadjadj
Summary: SARS-CoV-2 infection is more severe in patients undergoing rituximab (RTX) treatment. Humoral response to vaccination is severely impaired in patients already treated with RTX. A study evaluated the impact of RTX initiation on humoral response to SARS-CoV-2 vaccination and found that antibody titers declined after RTX initiation.
CLINICAL RHEUMATOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Ahmad Mroue, Stephane Roueff, Isabella Vanorio-Vega, Helene Lazareth, Oksana Kovalska, Adrien Flahault, Philippe Tuppin, Eric Thervet, Marie-Christine Iliou
Summary: Chronic kidney disease (CKD) frequently coexists with heart failure (HF) and sarcopenia, limiting the benefits of cardiac rehabilitation (CR). This study found that CR is beneficial for HF patients with reduced ejection fraction (HFrEF) regardless of their CKD stage. Thus, CKD should not prevent the prescription of CR for HFrEF patients.
JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION
(2023)
Article
Peripheral Vascular Disease
Marilucy Lopez-Sublet, Thomas Merkling, Nicolas Girerd, Constance Xhaard, Adrien Flahault, Erwan Bozec, Celine Leroy, Tomona Fujikawa, Allan Arthur Vaag, Alexandre Mebazaa, Caroline Michaela Kistorp, Barbara Heude, Jean Marc Boivin, Faiez Zannad, Sandra Wagner, Patrick Rossignol
Summary: Although preterm-born and low-birth-weight individuals have an increased risk of cardiovascular diseases in adulthood, little is known regarding early cardiovascular and renal damage (CVRD) or hypertension in adulthood. Our study investigated the association of birth weight with early CVRD markers as well as the heritability of birth weight in an initially healthy family-based cohort. The study found that birth weight was strongly and negatively associated with hypertension, and positively associated with distensibility in adults with normal BMI and with LVMI for higher birth weights. No associations were found with other CVRD markers.
JOURNAL OF HYPERTENSION
(2023)
Article
Education, Scientific Disciplines
Yann Nguyen, Alexandre Nuzzo, Ariane Gross, Oceane Minka, Matthieu Lilamand, Geoffrey Rossi, Manuel Sanchez, Catherine Legue, Annabelle Pourbaix, Alexy Tran Dinh, Sacha Rozencwajg, Lina Khider, Nathan Peiffer-Smadja, Donia Bouzid, Albert Faye, Tristan Mirault, Victoire de Lastours
Summary: The study aimed to evaluate the educational value of third-year medical students' participation in OSCE as standardized patients. The results showed that students who participated in OSCE as standardized patients performed better in their own subsequent OSCE exams and perceived beneficial effects on reducing stress, increasing preparedness, and improving communication skills. Therefore, this approach could be widely generalized to enhance student performance.
Article
Rheumatology
Laura Perray, Yann Nguyen, Gaelle Clavel Refregiers, Thibaud Chazal, Emmanuel Heron, Clara Pouchelon, Bertrand Dunogue, Nathalie Costedoat-Chalumeau, Anne Murarasu, Alexis Regent, Xavier Puechal, Benjamin Thoreau, Francois Lifermann, Julie Graveleau, Miguel Hie, Antoine Froissart, Antoine Baudet, Alban Deroux, Christian Lavigne, Sebastien Puigrenier, Rafik Mesbah, Thomas Moulinet, Claire Vasco, Sabine Revuz, Gregory Pugnet, Virginie Rieu, Anais Combes, Antoine Brezin, Benjamin Terrier
Summary: This retrospective case-control study compares the characteristics, treatment, and outcome of isolated ANCA-associated scleritis and idiopathic scleritis with negative ANCA tests. The study found that isolated ANCA-associated scleritis is more common in females and often requires systemic treatment with poorer efficacy. Furthermore, 30.7% of patients with ANCA-associated scleritis progressed to systemic ANCA-associated vasculitis. This highlights the importance of ANCA testing in the diagnosis and treatment of scleritis.
Article
Rheumatology
Julien Culerrier, Yann Nguyen, Omer Karadag, Sule Yasar Bilge, Tuba Demirci Yildrim, Tahir Saygin Ogut, Veli Yazisiz, Cemal Bes, Ayse Celfe, Ayten Yazici, Oznur Sadioglu Cagdas, Andreas Kronbichler, David Jayne, Philipp Gauckler, Alexis Regent, Vitor Teixeira, Sylvain Marchand-Adam, Pierre Duffau, Saskia Ingen- Housz-Oro, Celine Droumaguet, Baptiste Andre, Luminita Luca, Sarah Lechtman, Achille Aouba, Celine Lebas, Amelie Servettaz, Amandine Dernoncourt, Marc Ruivard, Anne-Marie Milesi, Vincent Poindron, Patrick Jego, Roberto Padoan, Paolo Delvino, Frederic Vandergheynst, Christian Pagnoux, Elaine Yacyshyn, Peter Lamprecht, Oliver Flossmann, Xavier Puechal, Benjamin Terrier
Summary: This retrospective multicentre study aimed to investigate the characteristics and outcome of ANCA-associated vasculitis (AAV) induced by anti-thyroid drugs (ATD) compared to primary AAV. The results showed that ATD-induced AAV mainly presented as microscopic polyangiitis (MPA), with the most common manifestations being skin involvement, arthralgia, and glomerulonephritis. However, ATD-induced MPA was less severe and had a lower risk of relapse compared to primary MPA.
Article
Rheumatology
Charlotte Laurent, Laure Ricard, Yann Nguyen, Jean Jacques Boffa, Eric Rondeau, Grigorios Gerotziafas, Ismail Elalamy, Sophie Deriaz, Claire De Moreuil, Virginie Planche, Cathererine Johanet, Francois Millot, Olivier Fain, Arsene Mekinian
Summary: The study aimed to evaluate the impact of the triple-positive profile in 204 APS patients. The results showed that triple-positive patients had a higher risk of relapse and obstetrical complications.
Article
Public, Environmental & Occupational Health
Jill Vanthienen, Marine Vassilev Petrov, Thuy Mai Luu, Anik Cloutier, Anke Raaijmakers, Jan A. Staessen, Zhenyu Zhang, Thomas Salaets, Annouschka Laenen, Anne Smits, Anne-Monique Nuyt, Adrien Flahault, Karel Allegaert
Summary: The study found no significant difference in QT(c-Bazett) intervals between former preterm and/or extremely low birth weight cases and term-born controls.
Article
Dermatology
Etienne Canoui, Geoffrey Rossi, Yann Nguyen, Emmanuel Lafont, Benjamin Rossi, Olivier Roux, Safi Dokmak, Frederic Bert, Veronique Leflon-Guibout, Bruno Fantin, Agnes Lefort
Summary: In this study, 15 cases of C-PLA and 292 cases of B-PLA were retrospectively analyzed to compare their clinical, microbiological characteristics, management, and outcome. It was found that a history of malignancy, liver abscess, and severe sepsis were associated with the occurrence of C-PLA. C-PLA was also found to have a higher risk of recurrence.
Article
Transplantation
Rayan Affes, Anne-Laure Lapeyraque, Camille Laroche, Roxane Labrosse, Alexandra Cambier, Emile Demers, Adrien Flahault
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Rheumatology
Yann Nguyen, Benoit Blanchet, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Joensen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Veronique Le Guern, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Nathalie Costedoat-Chalumeau
Summary: The study aimed to assess the association between severe nonadherence to hydroxychloroquine (HCQ), analyzed by HCQ serum levels, and risks of systemic lupus erythematosus (SLE) flares, damage, and mortality rates. Severe nonadherence was found to be independently associated with increased risk of SLE flares, early damage, and five-year mortality.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Hematology
Romain Stammler, Yann Nguyen, Cecile Yelnik, Veronique Le Guern, Marc Lambert, Romain Paule, Eric Hachulla, Luc Mouthon, Anastasia Dupre, Felix Ackermann, Virginie Dufrost, Denis Wahl, Bertrand Godeau, Gaelle Leroux, Ygal Benhamou, Estibaliz Lazaro, Eric Daugas, Holy Bezanahary, Arsene Mekinian, Jean-Charles Piette, Nathalie Morel, Nathalie Costedoat-Chalumeau
Summary: This study analyzed the prevention of catastrophic antiphospholipid syndrome (CAPS), focusing on anticoagulation before CAPS episodes. The results indicated that the major precipitating factors of CAPS were infections, pregnancy, and surgery. Among patients with previous APS diagnosis, the proportion of using vitamin K antagonists (VKA) was low and many patients had a subtherapeutic international normalized ratio (INR) below 2, suggesting suboptimal anticoagulation management. These findings strongly suggest that inadequate anticoagulation can trigger CAPS.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Respiratory System
Yousra Kherabi, Thibaud Chazal, Jean-Francois Emile, Wassim Allaham, Elise Mallart, Victoire de Lastours, Julien Haroche, Yann Nguyen
Summary: Erdheim-Chester disease (ECD) is a rare histiocytic disorder with approximately 1500 reported cases worldwide, primarily affecting men aged 50 to 70. The disease commonly presents with bone involvement, perirenal infiltration causing a hairy kidney appearance, and a coated appearance of the aorta. Lung involvement in ECD is less frequent, with manifestations including pleural infiltration and interstitial lung disease. We present a case of a 76-year-old woman with recurrent pleuropneumonia revealing ECD.
RESPIRATORY MEDICINE CASE REPORTS
(2023)
